Patents by Inventor Yongke Zhang

Yongke Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-CD40 ANTIBODIES AND METHODS OF USE
    Publication number: 20230406948
    Abstract: The present invention provides high affinity anti-CD40 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases.
    Type: Application
    Filed: March 13, 2023
    Publication date: December 21, 2023
    Inventors: Yongke ZHANG, Guo-Liang YU, Weimin ZHU
  • ANTI-CD40 ANTIBODIES AND METHODS OF USE
    Publication number: 20220049005
    Abstract: The present invention provides high affinity anti-CD40 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases.
    Type: Application
    Filed: April 7, 2021
    Publication date: February 17, 2022
    Inventors: Yongke ZHANG, Guo-Liang YU, Weimin ZHU
  • ANTI-CD40 ANTIBODIES AND METHODS OF USE
    Publication number: 20220049006
    Abstract: The present invention provides high affinity anti-CD40 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases.
    Type: Application
    Filed: April 15, 2021
    Publication date: February 17, 2022
    Inventors: Yongke ZHANG, Guo-Liang YU, Weimin ZHU
  • Anti-CD40 antibodies
    Patent number: 11001637
    Abstract: The present invention provides high affinity anti-CD40 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases.
    Type: Grant
    Filed: December 19, 2016
    Date of Patent: May 11, 2021
    Assignee: Apexigen, Inc.
    Inventors: Yongke Zhang, Guo-Liang Yu, Weimin Zhu
  • CD19-CD20 BISPECIFIC AND DUAL PASSWAY CAR-T AND METHODS FOR USE THEREOF
    Publication number: 20210079111
    Abstract: A CAR system with multiple antibodies targeting antigens associated with different types of B-cell malignancies. The antigens recognized by the dual signal CAR system are selected from the group CD19 and CD20. Also provided are compositions and methods for treating cancers in a human using engineered T-cells having the CAR system.
    Type: Application
    Filed: August 26, 2020
    Publication date: March 18, 2021
    Inventors: Yongke Zhang, Huijun Zhi
  • MULTI-FUNCTION AND MULTI-TARGETING CAR SYSTEM AND METHODS FOR USE THEREOF
    Publication number: 20200038443
    Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes and relates to administering a genetically modified T cell to express a CAR system wherein the CAR system comprises a polynucleotide encoding multiple signaling-modules with either multiple antibody targeting tumor specific antigen or with membrane bound cytokine to further enhance immune cell survival and proliferation. The multi-costimulatory signaling structure gave less toxicity than conventional CAR-T structures using CD28 signaling domain. A CAR system with multiple antibodies targeting different tumor specific antigen can target difference cancer cell populations simultaneously.
    Type: Application
    Filed: August 2, 2019
    Publication date: February 6, 2020
    Inventors: Yongke Zhang, Huijun Zhi
  • ANTI-RANKL ANTIBODIES AND METHODS OF USE
    Publication number: 20190309080
    Abstract: The present invention provides anti-RANKL monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of rheumatoid arthritis and other diseases.
    Type: Application
    Filed: February 27, 2019
    Publication date: October 10, 2019
    Inventors: Yongke Zhang, Xiaodong Yang, Guo-Liang Yu, Weimin Zhu
  • Anti-RANKL antibodies and methods of use
    Patent number: 10259878
    Abstract: The present invention provides anti-RANKL monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of rheumatoid arthritis and other diseases.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: April 16, 2019
    Assignee: APEXIGEN, INC.
    Inventors: Yongke Zhang, Xiaodong Yang, Guo-Liang Yu, Weimin Zhu
  • ANTI-CD40 ANTIBODIES AND METHODS OF USE
    Publication number: 20180273630
    Abstract: The present invention provides high affinity anti-CD40 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases.
    Type: Application
    Filed: March 13, 2018
    Publication date: September 27, 2018
    Inventors: Yongke ZHANG, Guo-Liang Yu, Weimin Zhu
  • Anti-CD40 antibodies
    Patent number: 9994640
    Abstract: The present invention provides high affinity anti-CD40 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases.
    Type: Grant
    Filed: May 12, 2017
    Date of Patent: June 12, 2018
    Assignee: Apexigen, Inc.
    Inventors: Yongke Zhang, Guo-Liang Yu, Weimin Zhu
  • Anti-IL-6 receptor antibodies and methods of use
    Patent number: 9951136
    Abstract: The present invention provides anti-IL-6R monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of rheumatoid arthritis and other diseases.
    Type: Grant
    Filed: May 2, 2014
    Date of Patent: April 24, 2018
    Assignee: APEXIGEN, INC.
    Inventors: Sum Wai Pierre Lee, Yaohuang Ke, Yongke Zhang
  • ANTI-CD40 ANTIBODIES AND METHODS OF USE
    Publication number: 20170246297
    Abstract: The present invention provides high affinity anti-CD40 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases.
    Type: Application
    Filed: May 12, 2017
    Publication date: August 31, 2017
    Inventors: Yongke Zhang, Guo-Liang Yu, Weimin Zhu
  • ANTI-CD40 ANTIBODIES AND METHODS OF USE
    Publication number: 20170233483
    Abstract: The present invention provides high affinity anti-CD40 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases.
    Type: Application
    Filed: December 19, 2016
    Publication date: August 17, 2017
    Inventors: Yongke ZHANG, Guo-Liang YU, Weimin ZHU
  • Anti-CD40 antibodies and methods of use
    Patent number: 9676861
    Abstract: The present invention provides high affinity anti-CD40 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases.
    Type: Grant
    Filed: October 30, 2013
    Date of Patent: June 13, 2017
    Assignee: Apexigen, Inc.
    Inventors: Yongke Zhang, Guo-Liang Yu, Weimin Zhu
  • Anti-CD40 antibodies
    Patent number: 9556278
    Abstract: The present invention provides high affinity anti-CD40 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases.
    Type: Grant
    Filed: January 14, 2016
    Date of Patent: January 31, 2017
    Assignee: Apexigen, Inc.
    Inventors: Yongke Zhang, Guo-Liang Yu, Weimin Zhu
  • Anti-KDR antibodies and methods of use
    Patent number: 9441042
    Abstract: The present invention provides anti-KDR monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of a variety of cancers, rheumatoid arthritis, diabetic retinopathy and other diseases associated with aberrant VEGF or KDR expression and/or activity.
    Type: Grant
    Filed: November 1, 2012
    Date of Patent: September 13, 2016
    Assignee: Apexigen, Inc.
    Inventors: Yaohuang Ke, Sum Wai Pierre Lee, Yongke Zhang, Guo-Liang Yu, Weimin Zhu
  • ANTI-CD40 ANTIBODIES AND METHODS OF USE
    Publication number: 20160208007
    Abstract: The present invention provides high affinity anti-CD40 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases.
    Type: Application
    Filed: January 14, 2016
    Publication date: July 21, 2016
    Inventors: Yongke ZHANG, Guo-Liang Yu, Weimin Zhu
  • Methods of inhibiting proliferation of CD40-expressing cancer cells with anti-CD40 antibodies
    Patent number: 9266956
    Abstract: The present invention provides high affinity anti-CD40 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases.
    Type: Grant
    Filed: February 3, 2015
    Date of Patent: February 23, 2016
    Assignee: Apexigen, Inc.
    Inventors: Yongke Zhang, Guo-Liang Yu, Weimin Zhu
  • ANTI-RANKL ANTIBODIES AND METHODS OF USE
    Publication number: 20160032001
    Abstract: The present invention provides anti-RANKL monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of rheumatoid arthritis and other diseases.
    Type: Application
    Filed: March 11, 2014
    Publication date: February 4, 2016
    Inventors: Yongke Zhang, Xiaodong Yang, Guo-Liang Yu, Weimin Zhu
  • ANTI-CD40 ANTIBODIES AND METHODS OF USE
    Publication number: 20150307616
    Abstract: The present invention provides high affinity anti-CD40 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases.
    Type: Application
    Filed: February 3, 2015
    Publication date: October 29, 2015
    Inventors: Yongke ZHANG, Guo-Liang YU, Weimin ZHU